| |
Home »
News » 01/06 »
ABaxter Healthcare gets European clearance for Kiovig
Baxter Healthcare gets European clearance for Kiovig
Date published: 26/01/2006
The
European Medicines Agency (EMEA) has issued marketing authorization for Baxter
Healthcare's Kiovig. Kiovig, the intravenous immunoglobulin (IVIG), can now be
used for replacement therapy in primary immunodeficiency disorders (PID),
myeloma or chronic lymphocytic leukaemia and a number of other cases including
for children with congenital AIDS and recurrent infections.
Baxter
Europe president Jim Utts said: "The launch of Kiovig is the latest step in
Baxter's efforts toward advancing the science of IVIG. "We are excited to offer
this new liquid IVIG to help meet the needs of physicians, healthcare
professionals and patients." Baxter, with the approval from EMEA, will be
allowed to market the therapy in all 25 European Union member states, along
with Norway and Iceland.
© Adfero Ltd
Disclaimer
AllAboutMedicalSales excludes any warranty, express or implied, as to
the quality, accuracy, timeliness, completeness or fitness for a particular
purpose of this briefing. AllAboutMedicalSales will not be liable for any
claims, penalties, losses, damages, costs, or expenses arising from the use of
or inability to use this briefing or from any unauthorised access to or
alteration of the Briefing. AllAboutMedicalSales makes no warranty that the
contents of this briefing are compatible with all computer systems and
browsers.
|
